The surgical robot spinout from University of Nebraska will use the series B financing, co-led by SinoPharm, to support it through its application for market clearance.
Virtual Incision, a US-based surgical robot developer spun out from University of Nebraska system, has raised $18m in a series B round co-led by SinoPharm Capital, the investment arm of pharmaceutical firm SinoPharm.
Venture capital firm Bluestem Capital co-led the round, which also featured PrairieGold Venture Partners and a range of undisclosed investors.
Bluestem Capital and PraireGold had previously participated in an $11.2m funding round for the company in 2015 and co-led its $2m series A round in 2010.…